NEW TREATMENT OPTIONS UNDER INVESTIGATION FOR PELVIC ORGAN PROLAPSE Design of next generation meshes using degradable polymers and stem cell based surgical constructs
Pelvic organ prolapse (POP) develops when tissues, pelvic floor muscles and ligaments that support the pelvic organs (bladder, uterus and bowel) are damaged, usually in childbirth. This injury causes the organs to shift, or ‘drop’, into the vagina or event outside of the body. This can lead to debilitating symptoms including poor bladder or bowel control and pain during sex
POP Facts
- 1 in 4 women globally in their 40s live with POP
- 1 in 2 women over 50 years of age live with POP
- $200 million annual cost to the Australian healthcare system
POP is a lifelong, potentially debilitating condition. Despite the high prevalence, there is no cure for POP.
Dr Shayanti Mukherjee, Research Group Head, Translational Tissue Engineering at the with her team at Hudson Institute of Medical Research is developing new ways to prevent and potential cure pelvic organ prolapse (POP). The technology aims to ultimately lead to safer and more effective treatment for women with pelvic organ prolapse (POP) using a woman’s own stem cells to boost the effectiveness of a degradable mesh.
Dr Shayanti Mukherjee specialises in innovative cell-based therapies for pelvic floor disorders and birth trauma injuries.
Dr Mukherjee’s research uses a woman’s own stem cells to create a 3D-printed degradable mesh, promising to avoid the complications that have plagued previous synthetic non-degradable meshes.
“By integrating cutting-edge techniques like electrospinning and 3D printing of materials and cells, I aim to revolutionise maternal urogynaecological health, offering transformative solutions and improving the wellbeing of women affected by this prevalent issue.”
“This research has the potential to revolutionise therapies for pelvic floor regeneration and enable personalised medicine for women,” she said.
“By advancing innovative cell-based therapies, we are on the brink of transforming the landscape of maternal urogynaecological health, promising a brighter and healthier future for women across the globe,” said Dr Mukherjee.
Source: Hudson Institute of Medical Research
-
Belonging in a medical device company
Edith de Boer is the HR Director for Zimmer Biomet in Australia and New Zealand. Her career originally was in telecommunications and consulting in Europe. After leaving The Netherlands, Edith worked into the Australian medical research industry, before moving into a human resources role at Zimmer Biomet. Edith spoke to Australian Health Journal about her role and the organisation.
-
Generosity of spirit in teaching
The Ramaciotti Medal for Excellence is considered one of the most prestigious awards in biomedical research in Australia and is highly sought after by researchers in the field.
In 2022, Professor Matthew Kiernan was the recipient of the Ramaciotti Medal for Excellence and the associated $50,000 award.
Australian Health Journal spoke with Professor Kiernan to hear about his journey in medicine and science to try and uncover and understand diseases and his generosity of spirit to pass on what he has learnt.
-
Nurse led micro-suction earwax removal service continues success
At the 2024 Telstra Best of Business Awards in February, Earworx was recognised as the National Championing Health Award winner. Lisa Hellwege, the Clinical Director and Founder of Earworx, expressed her gratitude to the entire team and their patients for their trust and support. Earworx specialises in providing professional earwax removal services led by trained nurses using a procedure called microsuction.
